Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Chrome Hldg CO (MEHCQ)

Chrome Hldg CO (MEHCQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 96,394
  • Shares Outstanding, K 27,541
  • Annual Sales, $ 189,900 K
  • Annual Income, $ -280,890 K
  • EBIT $ -199 M
  • EBITDA $ -176 M
  • 60-Month Beta 2.12
  • Price/Sales 0.52
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.21
  • Most Recent Earnings $-0.87 on 08/04/25
  • Next Earnings Date 12/16/25 [--]
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.4100 +45.23%
on 11/24/25
3.7200 -5.91%
on 12/04/25
+0.1500 (+4.48%)
since 11/05/25
3-Month
2.4100 +45.23%
on 11/24/25
4.2300 -17.26%
on 09/08/25
-0.7600 (-17.84%)
since 09/05/25
52-Week
0.4701 +644.52%
on 05/13/25
6.2100 -43.64%
on 06/09/25
-0.1100 (-3.05%)
since 12/05/24

Most Recent Stories

More News
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 13.80 (-2.89%)
TYRA : 22.81 (+2.33%)
DMAC : 9.34 (-0.11%)
XBI : 123.02 (+0.79%)
23andMe Holding Submits August 2025 Operating Report

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

MEHCQ : 3.5000 (-2.78%)
23andMe Files Second Amended Bankruptcy Plan

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

MEHCQ : 3.5000 (-2.78%)
TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets

SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that...

MEHCQ : 3.5000 (-2.78%)
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation

MEHCQ : 3.5000 (-2.78%)
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

MEHCQ : 3.5000 (-2.78%)
REGN : 746.80 (+2.84%)
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

MEHCQ : 3.5000 (-2.78%)
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

MEHCQ : 3.5000 (-2.78%)
REGN : 746.80 (+2.84%)
23andMe Provides Update Regarding Court-Supervised Sale Process

MEHCQ : 3.5000 (-2.78%)

Business Summary

23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition...

See More

Key Turning Points

3rd Resistance Point 3.6833
2nd Resistance Point 3.6267
1st Resistance Point 3.5633
Last Price 3.5000
1st Support Level 3.4433
2nd Support Level 3.3867
3rd Support Level 3.3233

See More

52-Week High 6.2100
Fibonacci 61.8% 4.0174
Last Price 3.5000
Fibonacci 50% 3.3400
Fibonacci 38.2% 2.6627
52-Week Low 0.4701

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar